Innovent presents long-term survival data for IBI363 in immunotherapy-resistant NSCLC
June 01, 2026 | 14:28
Innovent announced long-term follow-up results from a proof-of-concept study of IBI363 showing robust survival benefits in advanced immunotherapy-resistant non-small cell lung cancer at ASCO 2026.
Mobile Version